Open an account

Solventum

SOLV · NYSE

$86.39+$1.34 (+1.58%)TodayMarket closed ·
Prev close $85.05

About SOLV

Solventum Corp. operates as a health care company. The company is headquartered in St. Paul, Minnesota and currently employs 20,000 full-time employees. The company went IPO on 2024-03-26. The Company’s segments include MedSurg, Dental Solutions, and Health Information System. MedSurg is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (OEM). Dental Solutions is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, and restorative cement. Health Information Systems provides healthcare systems with software solutions, including computer-assisted physician documentation, and direct-to-bill and coding automation.

Employees
20,000
Headquarters
ST. PAUL, Minnesota
Listed
Mar 26, 2024
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
solventum.com

SOLV key statistics

Market cap
14.48B
Price-earnings ratio
10.41
Dividend yield
—
Average volume
925.64K
Volume
804.54K
Open price
$86.01
High today
$86.72
Low today
$85.21
52 Week high
$94.16
52 Week low
$62.38

Solventum (SOLV) at a glance

As of Oct 20, 2026, Solventum (SOLV) shares are priced at $86.39, giving the company a market cap of 14.48B and a price-to-earnings ratio of 10.41.

Today the stock has traded between $85.21 and $86.72. The current price is 1.4% above the day's low and 0.4% below its high.

Volume so far is 804.54K shares, in line with the average of 925.64K shares a day.

Over the past year Solventum has ranged from $62.38 to $94.16, and now sits 76% of the way up that range.

Solventum met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $2.55 per share against an estimate of $1.94.

The average analyst price target is $95.90, 11.0% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

64%of 11 analyst ratings say Buy
  • Buy63.6%
  • Hold27.3%
  • Sell9.1%
Price target · 16 analystsAvg $95.90
Low
$70.70
Now
$86.39
High
$118.65

SOLV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 10.8% on average.

  1. Q3 FY24: reported $1.64 per share against an estimate of $1.42
  2. Q4 FY24: reported $1.41 per share against an estimate of $1.35
  3. Q1 FY25: reported $1.34 per share against an estimate of $1.25
  4. Q2 FY25: reported $1.69 per share against an estimate of $1.47
  5. Q3 FY25: reported $1.50 per share against an estimate of $1.46
  6. Q4 FY25: reported $1.57 per share against an estimate of $1.53
  7. Q1 FY26: reported $1.48 per share against an estimate of $1.38
  8. Q2 FY26: reported $2.55 per share against an estimate of $1.94

SOLV news

  • Press releasePRNewswire

    Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*

  • Press releasePRNewswire

    Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026

  • Press releaseGlobe Newswire

    Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

  • Press releasePRNewswire

    Solventum to Participate in the 2026 Wells Fargo Healthcare Conference

  • Press releaseGlobe Newswire

    The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For

  • Press releasePRNewswire

    Solventum Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Solventum Announces Intent to Separate its Health Information Systems Business

  • Press releasePRNewswire

    Solventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026

Similar companies

Companies in the same industry as Solventum

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.